WEKO3
アイテム
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
http://hdl.handle.net/10069/23169
http://hdl.handle.net/10069/2316901fe6bdf-82d4-46c2-ab55-01306e72de0e
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
CCP67_331.pdf (127.3 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2010-05-26 | |||||
| タイトル | ||||||
| タイトル | Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Gefitinib | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Non-small cell lung cancer | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | SP-A | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | SP-D | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Yamaguchi, Hiroyuki
× Yamaguchi, Hiroyuki× Soda, Hiroshi× Nakamura, Yoichi× Takasu, Mineyo× Tomonaga, Nanae× Nakano, Hirofumi× Doi, Seiji× Nakatomi, Katsumi× Nagashima, Seiji× Takatani, Hiroshi× Fukuda, Minoru× Hayashi, Tomayoshi× Tsukamoto, Kazuhiro× Kohno, Shigeru |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | PURPOSE: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefitinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment. METHODS: We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status </=3, age </=80 years, and stage IIIB-IV disease. In addition, EGFR mutations were analyzed in 24 patients. RESULTS: Multivariate analysis showed that favorable progression-free survival (PFS) after gefitinib treatment was associated with adenocarcinoma and high serum SP-D levels before treatment. EGFR mutation analysis of 24 patients showed that 16 patients had exon 19 deletion and/or exon 21 point mutations. EGFR mutations were significantly correlated with response to gefitinib and serum SP-D levels before treatment was significantly high in patients with the EGFR mutations. Serum SP-A levels were not associated with PFS. CONCLUSIONS: The present study showed that measurement of serum SP-D levels before treatment in patients with NSCLC may be a new surrogate marker for predicting the response to gefitinib. | |||||
| 内容記述 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | The original publication is available at www.springerlink.com | |||||
| 書誌情報 |
Cancer chemotherapy and pharmacology 巻 67, 号 2, p. 331-338, 発行日 2011-02 |
|||||
| 出版者 | ||||||
| 出版者 | Springer Berlin | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 03445704 | |||||
| EISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 14320843 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00598397 | |||||
| PubMed番号 | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 20401612 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1007/s00280-010-1325-x | |||||
| 権利 | ||||||
| 権利情報 | © Springer-Verlag 2010 | |||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
| 関係URI | ||||||
| 関連名称 | http://hdl.handle.net/10069/26688 | |||||
| 引用 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Cancer Chemotherapy and Pharmacology, 67(2), pp.331-338; 2011 | |||||
